Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice

Inflammation Research

Volumn 58, Issue 11, 2009, Pages 819-827

  Byrnes, John J ^a   Gross, Stefan ^a   Ellard, Courtney ^a   Connolly, Kelly ^a   Donahue, Stephen ^a   Picarella, Dominic ^a  

^a Ore Pharmaceuticals Inc   (United States)

Author keywords

Angiotensin; Animal model; Crohn's disease; Dextran sodium sulfate; Inflammatory bowel disease

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; DEXTRAN SULFATE; GL 1001; MYELOPEROXIDASE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; COLON; CONTROLLED STUDY; DESCENDING COLON; DIARRHEA; DRUG EFFECT; DRUG MEGADOSE; ENTERITIS; FECES ANALYSIS; FEMALE; HISTOPATHOLOGY; INTESTINAL BLEEDING; MOUSE; NONHUMAN; OCCULT BLOOD; RECTUM PROLAPSE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BODY WEIGHT; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMIDAZOLES; INFLAMMATORY BOWEL DISEASES; LEUCINE; MICE; MICE, INBRED BALB C; PEPTIDYL-DIPEPTIDASE A; PEROXIDASE; RANDOM ALLOCATION;

EID: 70349954913     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-009-0053-3     Document Type: Article

References (49)

1. EV Loftus 2004 Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences Gastroenterol 126 1504 17 10.1053/j.gastro.2004.01.063 (Pubitemid 38649869)
2. DK Podolsky 2002 Inflammatory bowel disease N Engl J Med 347 417 29 12167685 10.1056/NEJMra020831 1:CAS:528:DC%2BD38XlvFKrt7s%3D (Pubitemid 34851835)
3. JH Cho 2008 The genetics and immunopathogenesis of inflammatory bowel disease Nat Rev 8 458 466 1:CAS:528:DC%2BD1cXmt1Ojt7o%3D
4. JA Katz 2007 Management of inflammatory bowel disease in adults J Dig Dis 8 65 71 17532817 10.1111/j.1443-9573.2007.00287.x 1:CAS:528: DC%2BD2sXnsFSlsb0%3D (Pubitemid 46773616)
5. LJ Derijks LP Gilissen PM Hooymans DW Hommes 2006 Review article: thiopurines in inflammatory bowel disease Aliment Pharmacol Ther 24 715 729 16918876 10.1111/j.1365-2036.2006.02980.x 1:CAS:528:DC%2BD28XhtFGqsrvJ (Pubitemid 44244896)
6. PL Kozuch SB Hanauer 2006 General principles and pharmacology of biologics in inflammatory bowel disease Gastroenterol Clin N Am 35 757 73 10.1016/j.gtc.2006.09.005 (Pubitemid 44791839)
7. M Donoghue F Hsieh E Baronas K Godbout M Gosselin N Stagliano M Donovan B Woolf K Robison R Jeyaseelan RE Breitbart S Acton 2000 A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Circ Res 87 1 9
8. SR Tipnis NM Hooper R Hyde E Karran G Christie AJ Turner 2000 A human homolog of angiotensin converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase J Biol Chem 275 33238 43 10924499 10.1074/jbc.M002615200 1:CAS:528:DC%2BD3cXnvVOqtbw%3D (Pubitemid 30808528)
9. DW Lambert NM Hooper AJ Turner 2008 Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system Biochem Pharmacol 75 781 6 17897633 10.1016/j.bcp.2007.08.012 1:CAS:528:DC%2BD1cXhsFymtLk%3D (Pubitemid 351174108)
10. C Vickers P Hales V Kaushik L Dick J Gavin J Tang K Godbout T Parsons E Baronas F Hsieh S Acton M Patane A Nichols PJ Tummino 2002 Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase (ACE2) J Biol Chem 277 14838 43 11815627 10.1074/jbc.M200581200 1:CAS:528:DC%2BD38XjslSgsbo%3D (Pubitemid 34952556)
11. SB Gurley TM Coffman 2008 Gene targeting studies of ACE2 in cardiovascular physiology: mixed messages Exp Physiol 93 538 42 18376006 10.1113/expphysiol.2007.040014 1:CAS:528:DC%2BD1cXnvFChtrY%3D (Pubitemid 351595062)
12. GY Oudit MA Crackower PH Backx JM Penninger 2003 The role of ACE2 in cardiovascular physiology Trends Cardiovasc Med 13 93 101 12691672 10.1016/S1050-1738(02)00233-5 1:CAS:528:DC%2BD3sXis12ks7w%3D (Pubitemid 36411803)
13. I Hamming ME Cooper BL Haagmans NM Hooper R Korstanje ADME Osterhaus W Timens AJ Turner G Navis H van Goor 2007 The emerging role of ACE2 in physiology and disease J Pathol 212 1 11 17464936 10.1002/path.2162 1:CAS:528: DC%2BD2sXmt1eisL4%3D (Pubitemid 46746284)
14. I Hamming W Timens MLC Bulthuis AT Lely GJ Navis H van Goor 2004 Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis J Pathol 203 631 7 15141377 10.1002/path.1570 1:CAS:528:DC%2BD2cXlsVWktbY%3D (Pubitemid 38714099)
15. D Harmer M Gilbert R Borman KL Clark 2002 Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme FEBS Lett 532 107 10 12459472 10.1016/S0014-5793(02)03640-2 1:CAS:528: DC%2BD38XovFGksrs%3D (Pubitemid 35375876)
16. F Gembardt A Sterner-Kock H Imboden M Spalteholz F Reibitz HP Schultheiss WB Siems T Walther 2005 Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents Peptides 26 1270 7 15949646 10.1016/j.peptides.2005.01.009 1:CAS:528:DC%2BD2MXltFakt7s%3D (Pubitemid 40798085)
17. K Hirasawa Y Sato Y Hosoda T Yamamoto H Hanai 2002 Immunohistochemical localization of angiotensin II receptor and local renin-angiotensin system in human colonic mucosa J Histochem Cytochem 50 275 82 11799146 1:CAS:528:DC%2BD38XhtV2htL4%3D
18. Malstrom S, Tyler S, Ellard C, Collins H, Coopersmith R, Barnes T, White D, Tartaglia L. Use of in vivo bio-photonic imaging to identify novel therapeutic utility for use of the ACE2 inhibitor GL1001 for treating inflammatory disorders of the gastrointestinal tract. Paper presented at IBC 13th annual world congress, drug discovery & development of innovative therapeutics 2008 Aug; Boston, MA.
19. Malstrom S, Ellard C, Collins H, Coopersmith B, Barnes T, White D, Dimitrov L, Tartaglia L. Using in vivo biophotonic imaging in the repositioning of an ACE2 inhibitor. Paper presented at GTCbio conference, imaging in preclinical and clinical drug development 2007 Mar; Boston, MA.
20. NA Dales AE Gould JA Brown EF Calderwood B Guan CA Minor JM Gavin P Hales VK Kaushik M Stewart PJ Tummino CS Vickers TD Ocain MA Patane 2002 Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors J Am Chem Soc 124 11852 3 12358520 10.1021/ja0277226 1:CAS:528:DC%2BD38XmvVykur4%3D
21. LM Guzman S Odate CA Boiselle SB Gross JL Wallace R Coopersmith TM Barnes S Malstrom S Tyler C Ellard L Bourque JJ Byrnes M Jacobson S Donahue 2008 GL1001 inhibition of ACE2 is gastroprotective in rat models of gastritits Inflamm Bowel Dis S14 S14
22. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
23. K Somersalo OP Salo F Bjorksten KK Mustakalio 1990 A simplified Boyden chamber assay for neutrophil chemotaxis based on quantitation of myeloperoxidase Anal Biochem 185 238 42 2160202 10.1016/0003-2697(90)90286-I 1:CAS:528:DyaK3cXhslKms70%3D
24. LG Axelsson E Landstrom AC Bylund-Fellenius 1998 Experimental colitis induced by dextran sulfate sodium in mice: beneficial effects of sulphasalazine and olsalazine Aliment Pharmacol Ther 12 925 34 9768537 10.1046/j.1365-2036. 1998.00357.x 1:CAS:528:DyaK1cXmtlOqsbY%3D (Pubitemid 28428959)
25. Murthy S, Flanigan A. Animal models of inflammatory bowel disease. In: Morgan DW, Marshall LA, editors. In vivo models of inflammation. Basel: Birkhauser-Verlag, 1999. p. 205-29.
26. U Werner I Szelenyi 1992 Measurement of MPO activity as model for detection of granulocyte infiltration into different tissues Inflamm Res 36 C101 3
27. KA Duggan FAO Mendelsohn NR Levens 1989 Angiotensin receptors and angiotensin I-converting enzyme in rat intestine Am J Physiol Gastrointest Liver Physiol 257 G504 10 1:CAS:528:DyaL1MXmt1GqtLw%3D
28. M Paul AP Mehr R Kreutz 2006 Physiology of local renin-angiotensin systems Physiol Rev 86 747 803 16816138 10.1152/physrev.00036.2005 1:CAS:528:DC%2BD28XnsFGgtLk%3D (Pubitemid 44033382)
29. R Jaszewski V Tolia MN Ehrinpreis JH Bodzin RR Peleman R Korlipara JV Weinstock 1990 Increased colonic mucosal angiotensin I and II concentrations in Crohn's colitis Gastroenterol 98 1543 8 1:STN:280:DyaK3c3kvFKntA%3D%3D
30. T Matsuda J Suzuki K Furuya M Masutani Y Kawakami 2001 Serum angiotensin I-converting enzyme is reduced in Crohn's disease and ulcerative colitis irrespective of genotype Am J Gastroenterol 96 2705 10 11569699 10.1111/j.1572-0241.2001.03945.x 1:CAS:528:DC%2BD3MXns1ygsLg%3D
31. K Katada N Yoshida T Suzuki T Okuda K Mizushima T Takagi H Ichikawa Y Naito G Cepinskas T Yoshikawa 2008 Dextran sulfate sodium-induced acute colonic inflammation in angiotensin II type 1a receptor deficient mice Inflamm Res 57 84 91 18288458 10.1007/s00011-007-7098-y 1:CAS:528:DC%2BD1cXjt1egt7g%3D (Pubitemid 351302060)
32. AU Spencer H Yang EQ Hazhija BE Wildhaber JK Greenson DH Teitelbaum 2007 Reduced severity of a mouse colitis model with angiotensin converting enzyme inhibition Dig Dis Sci 52 1060 70 17342403 10.1007/s10620-006-9124-2 1:CAS:528:DC%2BD2sXjsVSjtrs%3D (Pubitemid 46481233)
33. OI Santiago E Rivera L Ferder CB Appleyard 2008 An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis Regul Pept 146 250 9 18023891 10.1016/j.regpep.2007.10.004 1:CAS:528: DC%2BD1cXosFKnsA%3D%3D
34. M Ruiz-Ortega O Lorenzo Y Suzuki M Ruperez J Egido 2001 Proinflammatory actions of angiotensins Curr Opin Nephrol Hypertens 10 321 9 11342793 10.1097/00041552-200105000-00005 1:STN:280:DC%2BD3Mzps1WhtQ%3D%3D (Pubitemid 32424019)
35. NJ Dagenais F Jamali 2005 Protective effects of angiotensin II interruption: evidence for anti-inflammatory actions Pharmacotherapy 25 1213 29 16164395 10.1592/phco.2005.25.9.1213 1:CAS:528:DC%2BD2MXhtVGisbvK (Pubitemid 41244813)
36. S Guimaraes H Pinheiro 2005 Functional evidence that in the cardiovascular system AT1 angiotensin II receptors are AT1B prejunctionally and AT1A postjunctionally Cardiovasc Res 67 208 15 15953595 10.1016/j.cardiores. 2005.04.015 1:CAS:528:DC%2BD2MXlvFKrsbY%3D (Pubitemid 40943613)
37. J Georgsson U Rosenstrom C Wallinder H Beaudry B Plouffe G Lindeberg M Botros F Nyberg A Karlen N Gallo-Payet A Hallberg 2006 Short pseudopeptides containing turn scaffolds with high AT2 receptor affinity Bioorg Med Chem 14 5963 72 16753301 10.1016/j.bmc.2006.05.019 1:CAS:528:DC%2BD28Xntl2guro%3D (Pubitemid 44080582)
38. F Fyhrquist O Saijonmaa 2008 Renin-angiotensin system revisited J Intern Med 264 224 36 18793332 10.1111/j.1365-2796.2008.01981.x 1:STN:280: DC%2BD1cngsFOmtQ%3D%3D
39. U Rosenstrom C Skold G Lindeberg M Botros F Nyberg A Hallberg A Karlen 2004 Synthesis and AT2 receptor-binding properties of angiotensin II analogues J Pept Res 64 194 201 15485557 10.1111/j.1399-3011.2004.00184.x 1:STN:280:DC%2BD2crmt1yqug%3D%3D (Pubitemid 39446661)
40. S Han G Wang S Qiu C de la Motte HQ Wang G Gomez EW Englander GH Greeley 2007 Increased colonic apelin production in rodents with experimental colitis and in humans with IBD Regul Pept 142 131 7 17391779 10.1016/j.regpep.2007.02. 002 1:CAS:528:DC%2BD2sXmsFKhtLo%3D (Pubitemid 46899240)
41. M Peracchi MT Bardella F Caprioli S Massironi D Conte L Valenti C Ronchi P Beck-Peccoz M Arosio L Piodi 2006 Circulating ghrelin levels in patients with inflammatory bowel disease Gut 55 432 3 16474110 10.1136/gut.2005.079483 1:STN:280:DC%2BD28%2Fos1ejsQ%3D%3D (Pubitemid 43268285)
42. GJ Sanger 2008 Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases Drug Discov Today 13 234 9 18342799 10.1016/j.drudis.2007.10.024 1:CAS:528:DC%2BD1cXjsVSjsbk%3D
43. M Granado T Priego AI Martin MA Villanúa A López- Calderón 2005 Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats Am J Physiol Endocrinol Metab 288 486 92 10.1152/ajpendo.00196.2004 (Pubitemid 40250542)
44. T Waseem M Duxbury H Ito SW Ashley MK Robinson 2008 Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways Surgery 143 334 42 18291254 10.1016/j.surg.2007.09.039
45. T Brzozowski PC Konturek SJ Konturek S Kwiecien D Drozdowicz W Bielanski R Pajdo A Ptak A Nikiforuk WW Pawlik EG Hahn 2004 Exogenous and endogenous ghrelin in gastroprotection against stress-induced gastric damage Regul Pept 120 39 51 15177919 10.1016/j.regpep.2004.02.010 1:CAS:528:DC%2BD2cXks1Wktb0%3D (Pubitemid 38726190)
46. E Gonzalez-Rey A Chorny M Delgado 2006 Therapeutic action of ghrelin in a mouse model of colitis Gastroenterology 130 1707 20 16697735 10.1053/j.gastro.2006.01.041 1:CAS:528:DC%2BD28Xls1Witro%3D (Pubitemid 43668852)
47. DK Lee SR George BF O'Dowd 2006 Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity Trends Pharmocol Sci 27 190 4 10.1016/j.tips.2006.02.006 1:CAS:528: DC%2BD28Xjs1WmtLc%3D
48. HJ Chun ZA Ali Y Kojima RK Kundu AY Sheikh R Agrawal L Zheng NJ Leeper NE Pearl AJ Patterson JP Anderson PS Tsao MJ Lenardo EA Ashley T Quertermous 2008 Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis J Clin Invest 118 3343 54 18769630 1:CAS:528:DC%2BD1cXht1ChsrrI
49. MJ Kleinz AP Davenport 2005 Emerging roles of apelin in biology and medicine Pharmacol Ther 107 198 211 15907343 10.1016/j.pharmthera.2005.04.001 1:CAS:528:DC%2BD2MXlvVWgtLk%3D (Pubitemid 40916219)